Navigation Links
Oxford Finance Provides $10 Million Debt Financing to Celula

ALEXANDRIA, Va., April 30, 2015 /PRNewswire/ -- Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $10 million senior secured term loan agreement with Celula, Inc., a diagnostic testing company focused on improving the accuracy of diagnosing major diseases, enabling better patient care and improved outcomes.  Proceeds of the loan will be used to continue the development and expand the commercialization of its products in the U.S. and China.

"Celula has a seasoned management team that has developed a novel platform technology for diagnostic testing services," said Christopher A. Herr, senior managing director for Oxford Finance. "We are glad to provide debt financing to Celula to support the growth of the company and the expansion of its product line."

"We are pleased to be working with Oxford Finance as a capital partner," said Dr. Drew Senyei, chairman and chief executive officer of Celula. "Oxford understood our needs and provided a well structured debt facility that fit Celula's business plan. We are looking forward to further developing and bringing our technology and unique approach to the diagnostic market to improve patient care."

About Oxford Finance LLC

Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $2 billion in loans, with lines of credit ranging from $500 thousand to $75 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Massachusetts and North Carolina. For more information visit  

About Celula, Inc.

Celula is a diagnostic testing services company focused on significantly improving the accuracy of diagnosing major diseases, enabling better patient care and improved outcomes. Celula's unique cost effective "Integrated Diagnostic Accuracy" platform (IDA) consists of algorithmically combining proprietary technologies and non-proprietary technologies that together achieve significantly greater accuracy compared to current tests. The company's initial products will focus on improving the diagnostic accuracy of major women's diseases, specifically in gynecologic cancers and non-invasive prenatal diagnosis. Celula has an established infrastructure in both the U.S. and China allowing it to develop new products in a significantly more capital efficient manner as well as expand its commercial opportunities beyond the U.S.  For more information visit

SOURCE Oxford Finance LLC
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Oxford Performance Materials and Biomet Microfixation Join Forces
2. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
3. Oxford BioMedica Announces Update from ARVO 2013
4. Oxford University Press to publish BioScience journal starting in 2014
5. Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
6. Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up
7. Oxford BioTherapeutics to Present at 35th Cowen and Company Annual Health Care Conference in Boston
8. Oxford Finance Closes $20 Million Debt Facility with Inhibrx
9. GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine
10. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
11. Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer
Post Your Comments:
(Date:8/15/2020)... ... ... True Terpenes , the leading platform for terpene innovation, research and ... the medical potential of terpenes and the potential entourage effect , where the ... focused on expanding the recently launched line of effects-based terpenes - Terpology by ...
(Date:8/12/2020)... Mass. (PRWEB) , ... August 11, 2020 , ... ... $300,000 a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research ... in 2021 and 2022. The network is a consortium of academic research centers ...
(Date:8/12/2020)... Mich. (PRWEB) , ... August 12, 2020 , ... ... Group, Inc. (EMMA International), a global leader in FDA compliance consulting has ... the nation’s fastest-growing private companies. The list represents a unique look at the ...
(Date:8/3/2020)... ... August 03, 2020 , ... ... Jim Corrigan, President and CEO has been named one of the 100 most ... industry sectors, PharmaVoice 100 honorees are selected based on how they have inspired ...
Breaking Biology Technology:
(Date:8/3/2020)... ... August 03, 2020 , ... ... new partnership with medical equipment manufacturer, Spectrum Solutions, to provide COVID-19 saliva testing ... their laboratory supply chain for more than 10 years. Early in the COVID-19 ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to lead upcoming ... term focus on Type 2 diabetes and associated comorbidities. , Justin brings over ... and classes. As Chief Commercial Officer, Justin will lead Better Therapeutics’ ...
(Date:7/18/2020)... , ... July 16, 2020 , ... ... demonstrates the effectiveness of the Invictus Medical Neoasis™ active noise control device to ... study reported that the Neoasis™ device attenuated the alarm sounds from patient monitors, ...
Breaking Biology News(10 mins):